CNS β3-adrenergic receptor activation regulates feeding behavior, white fat browning, and body weight

Am J Physiol Endocrinol Metab. 2017 Sep 1;313(3):E344-E358. doi: 10.1152/ajpendo.00418.2016. Epub 2017 Jun 6.

Abstract

Pharmacological β3-adrenergic receptor (β3AR) activation leads to increased mitochondrial biogenesis and activity in white adipose tissue (WAT), a process commonly referred to as "browning", and transiently increased insulin release. These effects are associated with improved metabolic function and weight loss. It is assumed that this impact of β3AR agonists is mediated solely through activation of β3ARs in adipose tissue. However, β3ARs are also found in the brain, in areas such as the brain stem and the hypothalamus, which provide multisynaptic innervation to brown and white adipose depots. Thus, contrary to the current adipocentric view, the central nervous system (CNS) may also have the ability to regulate energy balance and metabolism through actions on central β3ARs. Therefore, this study aimed to elucidate whether CNS β3ARs can regulate browning of WAT and other aspects of metabolic regulation, such as food intake control and insulin release. We found that acute central injection of β3AR agonist potently reduced food intake, body weight, and increased hypothalamic neuronal activity in rats. Acute central β3AR stimulation was also accompanied by a transient increase in circulating insulin levels. Moreover, subchronic central β3AR agonist treatment led to a browning response in both inguinal (IWAT) and gonadal WAT (GWAT), along with reduced GWAT and increased BAT mass. In high-fat, high-sugar-fed rats, subchronic central β3AR stimulation reduced body weight, chow, lard, and sucrose water intake, in addition to increasing browning of IWAT and GWAT. Collectively, our results identify the brain as a new site of action for the anorexic and browning impact of β3AR activation.

Keywords: adipose tissue browning; appetite regulation; body weight; obesity.

MeSH terms

  • Adipose Tissue, Brown / drug effects*
  • Adipose Tissue, White / drug effects*
  • Adrenergic beta-3 Receptor Agonists / pharmacology*
  • Adrenergic beta-3 Receptor Antagonists / pharmacology*
  • Animals
  • Body Weight / drug effects*
  • Cell Line
  • Central Nervous System
  • Diet, High-Fat
  • Dioxoles / pharmacology*
  • Energy Metabolism / drug effects
  • Feeding Behavior / drug effects*
  • Gene Expression Profiling
  • Hypothalamus / cytology
  • Hypothalamus / drug effects
  • Hypothalamus / metabolism
  • Immunohistochemistry
  • Insulin / metabolism
  • Insulin Secretion
  • Iodide Peroxidase / genetics
  • Iodothyronine Deiodinase Type II
  • Male
  • Neurons / cytology
  • Neurons / drug effects
  • Propanolamines / pharmacology*
  • Proto-Oncogene Proteins c-fos / drug effects
  • Proto-Oncogene Proteins c-fos / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Adrenergic, beta-3 / drug effects*
  • Transcription Factors / genetics
  • Uncoupling Protein 1 / genetics

Substances

  • 3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate
  • Adrenergic beta-3 Receptor Agonists
  • Adrenergic beta-3 Receptor Antagonists
  • Dioxoles
  • Insulin
  • PRDM16 protein, rat
  • Propanolamines
  • Proto-Oncogene Proteins c-fos
  • Receptors, Adrenergic, beta-3
  • Transcription Factors
  • Ucp1 protein, rat
  • Uncoupling Protein 1
  • disodium (R,R)-5-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)-amino)propyl)-1,3-benzodioxole-2,3-dicarboxylate
  • Iodide Peroxidase